Welcome to Radiation Oncology
The mission of this department is three-fold: to deliver world-class care on a daily basis to our patients using the most advanced technologies available; to conduct groundbreaking basic, translational and clinical research; and to provide quality education to the next generation of medical practitioners and scientists.
Dr. Larry Kun is this year’s Memphis Business Journal Health Care Heroes Lifetime Achievement honoree for his 32 years of commitment and innovation at St. Jude Children’s Research Hospital. He joined St. Jude in 1984 to help establish a radiation therapy team that specialized in treating childhood cancer. Under his leadership, that program became one of the country’s most successful pediatric brain tumor programs. In 2013, he was appointed to Clinical Director and Executive Vice President. In 2016, Dr. Kun left St. Jude for Dallas to be closer to family. Soon after, he joined UT Southwestern as Professor and Director of Educational Programs for Radiation Oncology and Professor for Pediatrics.
U.S. News & World Report just released its 2017 list of top hospitals. UT Southwestern ranks #1 in the Dallas/Ft. Worth area and #2 in Texas. In addition, we nationally ranked in six specialties and are noted as high-performing in four conditions, including cancer. An honor to be recognized!
According to the American Brain Tumor Association, there are nearly 700,000 people in the U.S. living with a primary brain and central nervous system tumor, and nearly 17,000 this year will die from it. Glioblastoma represents 14.9 percent of all primary brain tumors and has the highest number of cases of malignant tumors with an estimated 12,390 new cases predicted in 2017.
Combination therapy with two immunotherapy drugs produces an unprecedented doubling of response rates from 20 percent to 40 percent, a new study shows.
Dallas-based UT Southwestern Medical Center’s Harold C. Simmons Comprehensive Cancer Center is the only site in Texas selected for a national cancer clinical trial. The Cancer Moonshot trial will focus on finding personal approaches to treat one type of blood cancer.